Stock A061250 HWAIL PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hwail Pharmaceutical Co.,Ltd.

Equities

A061250

KR7061250007

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
1,510 KRW +0.47% Intraday chart for Hwail Pharmaceutical Co.,Ltd. -3.02% -31.52%
Apr. 18 Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD. CI
Mar. 27 PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on August 21, 2023, has expired with 2,340,000 shares, representing 3.52% for KRW 4,980.33 million.
CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
CI
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) dropped from S&P Global BMI Index
CI
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
CI
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 1,519,180 shares, representing 2.23% for KRW 4,999.11 million.
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
CI
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
CI
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
CI
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 5.0000013 billion in funding from Osung Advanced Materials Co., Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A061250 Stock
  4. News Hwail Pharmaceutical Co.,Ltd.